Eleni Gkanatsiou

Stockholm, AB 11251, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

MALDI mass spectrometry imaging (MSI) reveals molecular and structural heterogeneity of amyloid-β in sporadic Alzheimer's disease and Down syndrome.

MALDI mass spectrometry imaging (MSI) reveals molecular and structural heterogeneity of amyloid-β in sporadic Alzheimer's disease and Down syndrome.

Journal: Acta neuropathologica communications

Published: December 08, 2025

Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.

Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.

Journal: Molecular and cellular neurosciences

Published: April 04, 2024

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.

Journal: Molecular and cellular neurosciences

Published: March 28, 2024

Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome.

Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome.

Journal: Acta neuropathologica

Published: February 02, 2024

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.

Journal: Scientific reports

Published: December 22, 2023

Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.

Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.

Journal: Journal of neurochemistry

Published: October 25, 2023

Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer's disease model mice.

Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer's disease model mice.

Journal: Nature aging

Published: June 19, 2023

Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides.

Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides.

Journal: Molecular neurobiology

Published: April 22, 2022

Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.

Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.

Journal: Molecular psychiatry

Published: July 17, 2021

Amyloid pathology and synaptic loss in pathological aging.

Amyloid pathology and synaptic loss in pathological aging.

Journal: Journal of neurochemistry

Published: October 30, 2020

Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.

Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.

Journal: Neuroscience letters

Published: September 02, 2020

Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.

Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.

Journal: Molecular psychiatry

Published: January 29, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026